<?xml version="1.0" encoding="UTF-8"?>
<p>Globally, acute gastroenteritis caused by RVA is a major public health concern, estimated to cause 215,000 deaths in children of &lt;5 years of age in 2013 [
 <xref rid="pone.0220387.ref013" ref-type="bibr">13</xref>,
 <xref rid="pone.0220387.ref014" ref-type="bibr">14</xref>]. Four countries (India, Nigeria, Pakistan and Democratic Republic of the Congo) accounted for almost half (45%) of deaths due to RVA in 2013 [
 <xref rid="pone.0220387.ref014" ref-type="bibr">14</xref>,
 <xref rid="pone.0220387.ref015" ref-type="bibr">15</xref>]. In the last decade, a large research data obtained on RVA associated disease burden and epidemiology helped in the implementations of more effective health policies including RVA vaccination [
 <xref rid="pone.0220387.ref016" ref-type="bibr">16</xref>]. In 2009, WHO has recommended the inclusion of RVA vaccines (Rotarix and RotaTeq) in the Extended program on immunization (EPI) worldwide [
 <xref rid="pone.0220387.ref017" ref-type="bibr">17</xref>,
 <xref rid="pone.0220387.ref018" ref-type="bibr">18</xref>]. As of August 2018, 98 countries have introduced rotavirus vaccine in their national immunization program including six high disease burden countries (Afghanistan, Angola, Ethiopia, India, Kenya and Pakistan) [
 <xref rid="pone.0220387.ref019" ref-type="bibr">19</xref>]. In the developed countries of Europe and America, both vaccines resulted in a significant drop in diarrhea associated deaths but proved to be less effective in developing countries of Asia and Africa [
 <xref rid="pone.0220387.ref016" ref-type="bibr">16</xref>,
 <xref rid="pone.0220387.ref020" ref-type="bibr">20</xref>]. The proposed hypothesis for lower vaccine efficacy in low income countries include interaction with maternal antibodies, malnutrition, host concomitant infections, RVA genotypes diversity and difference in gut micro flora [
 <xref rid="pone.0220387.ref021" ref-type="bibr">21</xref>,
 <xref rid="pone.0220387.ref022" ref-type="bibr">22</xref>].
</p>
